NIMOTOP

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Nimodipine

Available from:

Bayer Australia Ltd

Class:

Medicine Registered

Patient Information leaflet

NIMOTOP
®
 CMI 

1 
NIMOTOP
®

(NEE·MOE·TOP) 
_nimodipine_ 

CONSUMER MEDICINE INFORMATION 

WHAT IS IN THIS 
LEAFLET 
This leaflet answers some common 
questions about Nimotop. This 
leaflet does not contain all the 
available information. It does not 
take the place of talking to your 
doctor or pharmacist.    

All medicines have risks and 
benefits. Your doctor has weighed 
the risks of you taking Nimotop 
against the benefits they expect it 
will have for you. 

IF YOU HAVE ANY CONCERNS ABOUT 
TAKING THIS MEDICINE, ASK YOUR 
DOCTOR, NURSE OR PHARMACIST. 

KEEP THIS LEAFLET WITH THE 
MEDICINE.   
You may need to read it again 
WHAT NIMOTOP IS 
USED FOR 
Nimotop tablets and infusion 
solution are used to prevent or to 
treat a lack of blood supply in the 
brain caused by narrowing of the 
blood vessels after a haemorrhage 
(burst blood vessel in the brain). 

This medicine belongs to a group of 
drugs called calcium channel 
blockers. Nimotop works by 
relaxing the smooth muscle of the 
small blood vessels in the brain.  
This allows narrowed vessels to 
open up, thereby increasing blood 
flow, reducing blood pressure, and 
improving circulation. 

YOUR DOCTOR MAY PRESCRIBE THIS 
MEDICINE FOR ANOTHER USE. IF YOU 
WANT MORE INFORMATION, ASK YOUR 
DOCTOR. 

If you have any further questions on 
your Nimotop treatment, or are 
unsure of the information, please 
see your doctor, nurse or dispensing 
pharmacist, who will be able to 
assist you.

BEFORE YOU TAKE 
NIMOTOP 
_WHEN YOU MUST NOT TAKE IT _
DO NOT TAKE NIMOTOP TABLETS OR 
INFUSION SOLUTION IF YOU HAVE AN 
ALLERGY TO: 
  nimodipine, the active 
ingredient in Nimotop 
  any of the ingredients listed at 
the end of this leaflet. 

Some of the symptoms of an 
allergic reaction may include: 
  shortness of breath 
  wheezing or difficulty breathing 
  swelling of the face, lips, 
tongue or oth

Summary of Product characteristics

110401 NIMOTOP PI                           

1 
PRODUCT INFORMATION 

NIMOTOP
®

NIMODIPINE 

NAME OF THE MEDICINE 

Nimodipine belongs to the class of pharmacological agents
known as calcium 
channel blockers. Nimodipine is isopropyl (2 - methoxyethyl) 1,
4 - dihydro - 2, 6 - 
dimethyl - 4 - (3 - nitrophenyl) - 3, 5 -
pyridine - dicarboxylate. It is a racemic mixture 
with a molecular weight of 418.5 and a molecular formula of C
21
H
26
N
2
O
7
.  The CAS 
Registry Number is: 66085-59-4. The structural formula is:  

DESCRIPTION 

Nimodipine is a yellow crystalline substance, practically
insoluble in water. 

Nimodipine is light sensitive but to a much lesser degree than
nifedipine. 

Nimotop is available as tablets containing 30 mg nimodipine or a
0.2 mg/mL   
solution for infusion. Nimotop tablets contain cellulose
– microcrystalline, povidone, 
starch - maize, crospovidone, magnesium
stearate, hypromellose, macrogol 4000, 
titanium dioxide and iron oxide yellow as excipients. Nimotop
solution for infusion 
contains ethanol 96% (200 mg/mL), macrogol 400, sodium citrate
and citric acid – 
anhydrous as excipients. 

PHARMACOLOGY 

Nimodipine is a calcium channel blocking agent belonging
to the 1,4-dihydropyridine 
group. The mechanism(s) of nimodipine's
clinical benefit in patients with 
subarachnoid haemorrhage has not been fully elucidated. Current
evidence suggests 
that it may have a preferential cerebral vasodilator action and/or
a direct effect 
involving prevention of calcium overload in neurons. It dilates
the small resistance 
cerebral vessels and increases the cerebral blood flow, the
increased perfusion 
being generally more pronounced in brain regions with preliminary
damage and 
restricted circulation than in healthy